The management of a patient with severe sepsis is first to diagnose the infection, to collect samples immediately after diagnosis and to initiate promptly broad-spectrum antibiotic treatment. The choice of empirical antimicrobial therapy should be based on host characteristics, site of infection, local ecology and the pharmacokinetics and pharmacodynamics of the antibiotics. In severe infection, guidelines recommend the use of a combination of antibiotics. After results of cultures are obtained, treatment should be re-evaluated to either de-escalate or escalate the antibiotics. This is associated with optimal costs, decreased incidence of superinfection and reduced development of antimicrobial resistance. All these steps should be based on written protocols, and compliance to these protocols should be monitored continuously in order to detect violations and implement corrective procedures.
Introduction
Empirical antimicrobial therapy refers to the initiation of treatment prior to determination of a firm diagnosis. It is most often used when antibiotics are given to a patient before the specific micro-organism causing an infection is known. This is always the case in septic shock patients. As stated elsewhere, this therapy ranges from 'derived from experiment and observation rather than theory' at one extreme, to 'relying on medical quackery or uninfluenced by pathology or clinical tools' at the other. 1 Inappropriate empirical antimicrobial therapy is defined as the absence of antimicrobial agents directed against a specific class of micro-organisms and the administration of an antimicrobial agent to which the micro-organism responsible for infection was resistant. 'Broad-spectrum antibiotics' refers to antibiotics with activity against Pseudomonas aeruginosa, including imipenem-cilastatin, piperacillin-tazobactam, ceftazidime or ciprofloxacin. Limited-spectrum antibiotics will only refer to b-lactam antibiotics without activity against P. aeruginosa (essentially, ceftriaxone and amoxicillin-clavulanate). 2 
Principles
The driving force behind this strategy is the consistent finding that delay in the initiation of appropriate antibiotic therapy in patients with severe infection is associated with increased mortality. [2] [3] [4] [5] Patients in whom there is a suspicion of infection and with haemodynamic impairment, for example, requiring a fluid challenge or vasopressors, are candidates for receiving empirical antimicrobial therapy. Such treatment is also required in selected infections, for example, severe sepsis, meningitis, pneumonia, peritonitis, pyelonephritis or endocarditis, or in specific patient populations (Fig. 1) . The timing of antibiotic administration is critical, impacting on the outcome (Fig. 1 ). In patients with severe infection, any delay is associated with increased mortality and morbidity 6 and carers should not wait for the results of microbiological culture before introducing antibiotics in these groups of patients.
The selection of initial antibiotic therapy is based on the risk factors for specific pathogens, modified by knowledge of local patterns of antibiotic resistance and organism prevalence. 7 This treatment should be efficient against the bacteria involved in the suspected infection. Indeed, inappropriate empirical antibiotic therapy is widespread and associated with increased mortality in critically ill patients. For instance, increased mortality was seen in patients treated with empirical piperacillintazobactam therapy and infected by P. aeruginosa bacteraemia due to isolates with reduced piperacillintazobactam susceptibility. 8 The challenge is to provide an appropriate therapy without any microbiological documentation. In this setting, adherence to guidelines makes it possible to administer empirical antibiotic treatments effective against the most probable pathogens responsible for the potential infection. 9 A recent study showed that adherence to standard operating procedures is associated with a shorter duration of treatment of pneumonia, a shorter duration of mechanical ventilation and a shorter ICU stay. 10 Barriers to physicians' adherence to guidelines include awareness, familiarity, agreement with the guideline, belief that one can actually perform an appropriate behaviour, outcome expectancy (the expectation that a given behaviour will lead to a particular consequence), the ability to overcome the inertia of previous practice and the absence of external barriers to follow recommendations. 11 In order to minimise the risk of failure, empirical antimicrobial therapy is typically broad-spectrum. However, the major limitation to this approach is that it consistently leads to more antibiotic therapy than when the decision is based on the results of microbiological cultures. 12 This practice can be associated with the emergence of multidrug-resistant pathogens, infections due to Clostridium difficile and increased costs. 2 In parallel, as evidence for administering empirical antibiotics is not always found, 13, 14 it is important to determine the conditions when antibiotics must, absolutely, be prescribed to a given patient.
In all patients, empirical antibiotic regimens should be reassessed and adjusted as soon as culture and sensitivity results become available. This practice, usually implying de-escalation (but sometimes escalation if the pathogens are not covered), is associated with reduced costs, a decreased incidence of superinfection and minimal development of antimicrobial resistance.
2 Candida colonisation and invasive candidiasis in the ICU is a major nosocomial problem. There is a clear relationship between the use of antibacterial agents and subsequent candida colonisation. The consequences of antibiotic overuse are well described 15, 16 and beyond the scope of this review.
Timing
In each patient, the timing of the start of an antibiotic can be considered as emergency, urgent or delayed (Fig. 1) . Emergency and urgent are defined by the need for starting antibiotics within 1 h and within 6-8 h after diagnosis, respectively. Delayed antibiotic therapy is defined by the start of antibiotics 8-24 h after diagnosis. 17 In patients with severe sepsis or septic shock, observational studies have shown that the administration of antibiotics within the first hour after diagnosis is associated with improved survival. Each hour of delay in antibiotic administration after diagnosis is associated with an average decrease in survival of 7.6%; thus, every 10 min, survival is decreased by 1%. Current guidelines recommend prompt antimicrobial therapy in these patients. 18 Several observational studies have confirmed a strong association between prompt introduction of antibiotics and survival. [19] [20] [21] They underline the need to provide appropriate antibiotics within the first hour after sepsis identification. 22 Inappropriate initial antimicrobial therapy for septic shock occurs in approximately 20% of patients and is associated with a five-fold reduction in survival.
Choice of empirical antimicrobial therapy
A judicious choice of antimicrobial therapy should be based on the host characteristics, the site of infection, the local ecology and the pharmacokinetics and pharmacodynamics of antibiotics. Toxicity and costs are also considered. The choice between monotherapy and a combination of antibiotics is discussed below. Antimicrobial options for severe nosocomial infections are suggested in Table 1 . As guidelines are available that specifically describe the use of antibiotics in each condition, we have only reported the principles of antibiotic choice.
Host characteristics
For many years, the choice of antibiotics in the ICU depended on the duration of prior hospitalisation. The emergence of multiresistant bacteria in the community has made this concept obsolete and there is, at present, a population of patients who carry multiresistant bacteria. 23 Risk factors for multiresistant bacteria are the prescription of an antibiotic treatment within the previous 3 months; a length of stay (hospital or ICU) of more than 5 days (this period is reduced, if there is a high prevalence of multiresistant bacteria locally); and immunosuppression. In the presence of such risk factors, the spectrum of initial antibiotic treatment should include multiresistant bacteria.
Routine tracheal aspiration makes it possible to prescribe adequate antibiotic therapy in 95% of the patients in whom ventilator-associated pneumonia is ultimately diagnosed by culture. This often involves an antibiotic active against methicillin-resistant Staphylococcus aureus (MRSA), given with an antibiotic active against Gramnegative bacteria producing extended spectrum b-lactamase. For pneumonia, specific risk factors are prior hospitalisation for 2 days or more; residence in a nursing home or extended care facility; home infusion therapy or home wound care; chronic dialysis within 30 days; and, a family member with multiresistant bacteria. These factors are listed in Fig. 2 .
Site of infection
The site of infection is one of the major determinants in the choice of antibiotics (Table 1) . Respiratory tract (63%), abdomen (20%), bloodstream infections (15%) and urinary tract infections (14%) are the most frequent types of ICU infection reported. 23 For patients without risk factors for multiresistant bacteria, in other words, recent admission, no prior medical history and no recent antibiotic use, ventilator-associated pneumonia is generally due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Legionella sp., Mycoplasma pneumoniae, Chlamydia pneumoniae and viruses. For the Antibiotic therapy in patients with septic shock 319 patients with risk factors for multiresistant bacteria carriage, P. aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae and MRSA should be suspected.
Sixty percent of spontaneous bacterial peritonitis episodes are caused by Gram-negative enteric bacilliEscherichia coli and Klebsiella sp. being the most frequently isolated micro-organisms. In approximately 25% of cases, streptococci (frequently pneumococcus) and enterococci are involved. 24 Secondary peritonitis is always polymicrobial with Gram-negative bacteria (E. coli, Enterobacter sp., Klebsiella sp.), Gram-positive bacteria (enterococci in $20% of the cases) and anaerobes (Bacteroides sp. in $80% of the cases). For patients with identified risk factors, as defined in Fig. 2 or those with nosocomial peritonitis, multiresistant bacteria (including P. aeruginosa, Acinetobacter and MRSA) and yeasts should be suspected. In certain centres, extended-spectrum b-lactamase-carrying bacteria should be suspected and the empirical antibiotic treatment modified accordingly.
Skin infections are frequently polymicrobial. Suspected bacteria should be Streptococcus sp. (40%), S. aureus (30%), anaerobes (30%) and Gram-negative bacteria (10-20%). Bacterial cerebrospinal fluid infections in patients admitted from the community are due to S. pneumoniae (35%) and Neisseria meningitidis (32%). 25 In the ICU, they are related to intracerebral devices. Among 84 patients with ventriculostomy catheters, infections were related to Gram-negative bacilli [Acinetobacter sp. (50%)] and Grampositive cocci (29%). 26 
Knowledge of local ecology
Knowledge of local bacteriological patterns increases the likelihood of prescribing appropriate antimicrobial therapy. Regular surveillance cultures are recommended to assess the level of resistance in a specific unit. This process is useful to identify patients carrying multiresistant bacteria. Regular surveillance of cultures is also important to guide revisions of protocols in the light of local ecology changes. However, previously published results are not supportive; this might be due to a low prevalence of surveillance, 27, 28 and more recent data have shown a benefit. [29] [30] [31] The value of knowledge of the local ecology is illustrated in several studies. 32 In an observational study, using a local ecology-based protocol, 36 patients with late-onset ventilator-associated pneumonia were treated with b-lactam antibiotics with activity against P. aeruginosa. According to American Thoracic Society guidelines, 55 patients in this study should have received antibiotics. Thus, knowledge of the local 320 Textoris et al. ecology made it possible to use narrower spectrum antibiotics in 19 patients. Although knowledge of local epidemiological data is important for ICU-acquired infection, this is not true for community or healthcareacquired infections.
Pharmacokinetics and pharmacodynamics of antibiotics
The pharmacokinetics of antibiotics is modified in ICU patients by the large daily fluid requirements, acute changes in body weight, hypoalbuminaemia, oedema and low haematocrit, which lead to a marked change in elimination half-life, volume of distribution and clearance. 33 Sepsis increases capillary permeability, with the formation of a 'third-space', resulting in higher antibacterial clearances. On the other hand, multiple organ dysfunctions cause a decrease in antibacterial clearance. Consequently, monitoring of drug plasma concentrations should be encouraged whenever possible. Concentrationdependent antibiotics such as the aminoglycosides have their pharmacokinetics affected by an increased volume of distribution in sepsis, resulting in decreased peak serum concentrations. However, reduced renal clearance increases the likelihood of toxicity and once-daily dosing is strongly encouraged. The first dose should be the same in all patients, whatever the degree of renal insufficiency. It is recommended the prescription is limited to 3 days maximum. In this situation, no dose adaptation is needed. 34 For the b-lactam antibiotics, the serum levels must be above the minimum inhibitory concentrations (MIC) of the pathogens for all of the time between two injections. 35 For fluoroquinolone antibiotics, a high ratio of area under the curve to MIC is recommended (> 125 or 250 depending on the drug) and b-lactam antibiotics or quinolones should be administered at high doses or by continuous infusion (for example, ceftazidime). Vancomycin can also be administered by continuous infusion. 36 If there is a renal impairment, however, a corresponding dose reduction is needed. It has been shown that the glomerular filtration rate, mechanical ventilation and Antibiotic therapy in patients with septic shock 321 admission diagnosis may influence the achieved concentrations of ceftazidime. 37 Prediction of the penetration of antibiotics into solid organs remains a real challenge in the ICU. 38 Future studies using microdialysis will be useful to make progress in this field, and result in improved monitoring of antibiotic levels in the interstitial fluid.
Monotherapy versus combination therapy
Combinations of antibiotics are used to widen the spectrum of activity of antimicrobial therapy, increase the bactericidal activity and prevent the development of resistance. Textbooks and guidelines advise combinations for specific pathogens, mainly P. aeruginosa. 39 A suspicion of multiresistant bacteria leads to the use of a combination of antibiotics to enhance the spectrum and in septic shock, a combination of antibiotics is also recommended. Using a propensity-matched analysis, combination therapy was associated with decreased 28-day mortality in septic shock patients. The beneficial impact of combination therapy was seen when used for either Gram-positive or Gram-negative infections. However, it seems that the beneficial effect was restricted to patients treated with a b-lactam antibiotic as the pivotal antibiotic, in combination with aminoglycosides, fluoroquinolones or macrolides/clindamycin. 40 Combination therapy was also associated with significant reductions in ICU and hospital mortality. This finding has been confirmed by another observational study. 41 Of note, in a recent meta-analysis of studies of septic shock patients, it was observed that the use of combination therapy may be detrimental in patients with a mortality risk less than 15% compared with high-risk patients (risk of death >15%; odds ratio 1.53; 95% confidence interval 1.16-2.03, P ¼ 0.003). 42 There is a clear need for a randomised clinical trial.
Adjunctive measures before instituting antimicrobial therapy
Obtaining samples for microbiological investigation is obligatory before initiating empirical antimicrobial therapy. At least two sets of blood cultures should be obtained, with at least one set drawn percutaneously and one set drawn through each vascular device, unless the device was recently inserted (<3 to 5 days). Positive blood cultures make it possible to identify with certainty the pathogen(s) responsible for infection. 43 Cultures of urine, cerebrospinal fluid, wounds, respiratory secretions or other body fluids should be obtained as soon as possible, and before antimicrobial therapy is initiated, except in very specific situations such as meningococcal septicaemia with purpura fulminans. A sample of urine is required to detect antigens against Legionella pneumophila. Because antimicrobial therapy should be initiated within the first hour of the diagnosis of severe sepsis, appropriate cultures should be collected within the first minutes after sepsis is suspected. There is no reason why collecting samples should lead to delays in prescribing antibiotics.
In addition to antimicrobial therapy, it is essential to control the source of infection and modify factors that promote microbial growth or impair host antimicrobial defences. 44 This includes drainage of an abscess or local focus on infection, debridement of infected necrotic tissue and the removal of potentially infected devices. Delays in source control of an intra-abdominal infection is associated with increased mortality. 44 
De-escalation strategy
Empirical antimicrobial therapy in life-threatening situations should be initiated promptly and should have a broad spectrum of activity that covers all potential antimicrobial-resistant pathogens. However, to reduce excessive antimicrobial usage, broad-spectrum therapy should be de-escalated on the basis of microbiological data and clinical response. 45 This strategy has been used successfully in patients with pneumonia. 46 For example, in patients with ventilator-associated pneumonia, de-escalation was possible in approximately 50% of patients on day 3, including 54% of ventilator-associated pneumonia episodes due to P. aeruginosa, A. baumannii and MRSA. This strategy appears to limit the emergence of resistance when indirectly assessed by the profile of bacteria involved in recurrent infections. In observational studies, de-escalation therapy was shown to be safe in patients with septic shock or ventilator-associated pneumonia. In patients with infections related to multiply resistant bacteria, de-escalation is often not possible. 47 In patients with negative microbiology cultures, de-escalation is feasible if the patient is clinically stable. However, good quality studies demonstrating the safety of such a strategy in unstable patients are lacking. In the absence of randomised clinical trials, it is not possible to exclude a negative effect. Nevertheless, because of its benefit and lack of demonstrable risks, de-escalation therapy should be used whenever possible in critically ill patients with severe infections.
Shortening the duration of antimicrobial therapy
Shortening the duration of antibiotic therapy makes it possible to curtail the development of multiresistant bacteria, as well as the recurrence of infections caused by antimicrobial-resistant pathogens. In a randomised trial, the clinical pulmonary infection score 48 was used as the criterion for decision-making regarding antibiotic therapy. Patients with clinical pulmonary infection score of 6 or less were randomised to receive either standard therapy or ciprofloxacin monotherapy, with re-evaluation at day 3 and discontinuation of the ciprofloxacin if the score remained at 6 or less at day 3. Antibiotics were continued beyond day 3 in 90% of the patients in the standard therapy group compared with 28% in the experimental therapy group. Antimicrobial resistance, or superinfections or both, developed in 15% of the patients in the experimental group versus 35% of the patients in the standard therapy group. 49 In a prospective follow-up of patients with suspected ventilator-associated pneumonia and culture-negative broncho-alveolar lavage, discontinuation of antibiotics before day 3 appeared to be safe. 50 In conclusion, discontinuation of antibiotics, if appropriate cultures remain negative at day 3, appears safe in the patients making good clinical progress.
In patients with documented infection, a shortened duration of antimicrobial therapy minimises the emergence of resistance. A randomised clinical trial was designed to determine whether 8 days is as effective as 15 days of antibiotic treatment in patients with microbiologically proven ventilator-associated pneumonia. Among patients who received appropriate initial empirical therapy, with the possible exception of those developing non-fermenting Gram-negative bacillus infections, comparable clinical effectiveness was seen with both the 8-day and 15-day regimens. Among patients who developed recurrent infections, multiresistant pathogens emerged less frequently in those who had received 8 days of antibiotics. 51 Similarly, for patients with spontaneous bacterial peritonitis, there is no advantage in providing cefotaxime for more than 5 days. 52 Although no randomised clinical trials are available in patients with intra-abdominal infection, observational data encourage the reduction in the duration of antibiotic therapy. 53 Thus, discontinuing antibiotics if appropriate cultures are negative on day 3 and reducing the duration of antimicrobial therapy in proven infections are efficient ways to curtail the development of antimicrobial resistance.
Biomarkers may be useful in shortening the duration of antimicrobial therapy. Procalcitonin is a surrogate marker for estimating the likelihood of a bacterial infection. Procalcitonin-guided termination of antibiotic therapy may be a novel approach to reduce antibiotic overuse. Procalcitonin measurements, integrated into clinical algorithms, have been shown to reduce the duration of antibiotic courses by 25-65% in both hospitalised and more severely ill patients with community-acquired pneumonia and sepsis. 54 In contrast, to date, there is no evidence in support of using procalcitonin as a diagnostic marker for the initiation of antimicrobial treatment.
Writing a formal protocol based on local ecology
Antimicrobial guidelines are useful tools to control antibiotic prescription, which in turn reduce the development of multiresistant bacteria. Inappropriate treatment of infections is often due either to a lack of a suitable protocol, or to violation of the protocol where one exits. 55 In one observational study, antibiotic choices were determined by staff, including ICU and microbiologists. The choices were described in edited protocols, which were available in an electronic format on the ICU intranet. Interestingly, the four patients whose death was related to ventilator-associated pneumonia received treatments in violation of the guidelines. 9 When the selection of antibiotics is left solely to the discretion of the attending physician, the rate of appropriate use is very low (49%). 56 A formalised antibiotic discontinuation policy reduced the duration of antibiotics and may reduce the antibiotic resistance profile. 57 
Conclusion
An integrative strategy to assist management of antimicrobial treatment for septic patients should be formalised with written protocols. The strategy includes rational use of empirical antimicrobial therapy considering local patterns of susceptibility of pathogens, prior history of patients and their clinical status, followed by an early re-assessment to focus on the bacteria responsible for the infection. An infectious disease specialist may improve the accuracy of the prescription of antimicrobial treatment in the ICU. In other areas, antimicrobial therapy can be administered according to practice guidelines that are designed in collaboration with the microbiology department. Antimicrobial treatment may be evaluated during a weekly staff meeting. Implementing such strategies reduces the duration of antibiotic treatment, length of stay, and improves local adherence to the guidelines. De-escalation should be performed systematically whenever it is possible, but escalation can also be considered when an early clinical response is not obtained or initial treatment is inappropriate. After microbiological documentation, prolonged antimicrobial therapy should remain the exception to the rule. In most situations, 7 days of treatment is a desirable goal. All efforts should be made to avoid excessive antimicrobial use for non-life-threatening infections. However, there is a need for randomised clinical trials to provide support for this approach.
